Larimar Therapeutics announces FDA lift of partial clinical hold on nomlabofusp (CTI-1601) for Friedreich's Ataxia. Data from Phase 2 study shows well-tolerated treatment with significant frataxin level increases.
Goldman Sachs analyst reiterated Buy rating on Li Auto with $43.6 PT. Q1 revenue missed estimates, but new launches and sales network expansion expected to drive growth. Stock down nearly 30% in past 12 months.